What one share of Cadrenal Therapeutics holds
We are a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. As a result of our acquisition of a 12-lipoxygenase (“12-LOX”) platform of assets in December 2025 (as described in more detail below), we transitioned our primary strategic focus to the development of CAD-1005 for the treatment of immune-mediated and thrombotic disorders.
Cadrenal Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$4.87 |
|---|---|
| Cash and investments | $0.77 |
| Book value | $1.32 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$9.29 | $0.00 | −$3.93 | — | $8.86 |
| 2024 | — | −$8.73 | $0.01 | −$6.04 | $16.50 | $4.17 |
| 2025 | — | −$6.64 | $0.00 | −$6.32 | $16.50 | $1.17 |
Common questions about Cadrenal Therapeutics
How much does one share of Cadrenal Therapeutics earn?
Over the last 12 months, Cadrenal Therapeutics lost $4.87 for each share.
Does Cadrenal Therapeutics pay a dividend?
Cadrenal Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Cadrenal Therapeutics’s book value per share?
Cadrenal Therapeutics’s book value is $1.32 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Cadrenal Therapeutics have?
Each share of Cadrenal Therapeutics has $0.77 of cash and investments, as of June 30, 2026.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.